• 19/07/2021

    Publication: Results of the acceptability & feasibility study of the BPaL regimen

    A study, conducted by KNCV Tuberculosis Foundation and TB Alliance, shows that the adoption of BPal…

    Lees meer

  • 15/07/2021

    New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid

    TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure…

    Lees meer

  • 15/07/2021

    Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development

    15 July 2021, The Hague. To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions…

    Lees meer

  • 18/06/2021

    Welcome Dr. Harsh Vardhan, India’s Minister of Health, as new Chair of Stop TB Partnership

    KNCV Tuberculosis Foundation welcomes His Excellency Dr. Harsh Vardhan as the new chair of the Stop TB Partnership Board. We are confident that…

    Lees meer

  • 21/05/2021

    Appointments Board of Trustees

    May 11, 2021 the KNCV Members Association appointed Tjipke Bergsma and René Stumpel to the Board of Trustees and re-appointed…

    Lees meer

  • 18/05/2021

    The first TB patient in Nigeria to be treated with the BPaL regimen

    Ruth Iliya, who was first diagnosed in January 2021 is the first TB patient in Nigeria to be treated with…

    Lees meer

  • 18/05/2021

    New hope for drug resistant tuberculosis (TB) patients in Nigeria

    Nigeria is the first country in West Africa to provide people with tuberculosis (TB) access to the groundbreaking new BPaL…

    Lees meer

  • 12/05/2021

    Directory of TB vaccine clinical trial sites

    There are approximately 14 vaccine candidates for tuberculosis (TB). Over the upcoming 10 years these need to be tested in…

    Lees meer

  • 07/05/2021

    KNCV Nigeria won Cepheids Make it Happen Award

    KNCV Nigeria won the Cepheid Make it Happen Award for their Wellness on Wheels (WoW) project. This price…

    Lees meer

  • 24/03/2021

    Easy and child-friendly tuberculosis diagnosis in rural Ethiopia

    Mesay Gebre and her family of five live in Umiya, a mostly rural region in Ethiopia. They depend completely on…

    Lees meer

  • 18/03/2021

    Join us at the SOS Stoolbox Symposium!

    On 25 March 2021, KNCV Tuberculosis Foundation will hold a virtual symposium to celebrate the launch of the SOS Stoolbox.

    Lees meer

  • 16/03/2021

    KNCV Executive Director Mustapha Gidado: “Positive COVID test made me anxious”

    COVID19 is affecting us all, personally and professionally. Doctors, epidemiologists and infectious disease experts have also become infected and fallen…

    Lees meer

  • 08/03/2021

    TB diagnosed in time in Ethiopian family

    Selamawit, a mother of two, lives with her husband in Mole Kebele, Ethiopia. Her youngest daughter, who is now…

    Lees meer

  • 08/03/2021

    Iddirs in Ethiopia help diagnose tuberculosis in children

    In Ethiopia, female self-help associations, called “Iddirs”, help diagnose tuberculosis (TB) in children. These women receive training in which they…

    Lees meer

  • 01/02/2021

    Tell the Netherlands to invest in healthcare worldwide

    It’s become clear to everyone now; diseases know no borders. COVID-19 has shaken the whole world up about the importance…

    Lees meer
Bezoek Nederlandse website

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Cambodia
Eswatini
Ethiopia
Ghana
Indonesia
Kazachstan
Kenya
Kyrgyzstan
Malawi
Namibia
Nigeria
Rwanda
South Africa
Tajikistan
Tanzania
Ukraine
Vietnam
Zambia

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

KNCV’s Technical Assistance Strategy

New drugs & treatment regimens
Digital health solutions
Diagnosis & treatment of LTBI
TB Stigma reduction
Epidemiological measurement methodologies
New diagnostics and lab network design
People-Centered Framework for National Strategic Planning and HSS
Blended learning platform & methodologies

ASCENT
ASTTIE
Development of a comprehensive Digital Training Package
E-detect
GeneXpert MTB/RIF Test
IMPAACT4TB
PAVIA
People-Centered Framework for TB Programming
PODTEC
TB Alliance BPAL Project
The Global Fund to Fight AIDS, Tuberculosis and Malaria
TREATS

Our success stories

Challenge TB
Improved TB/HIV Prevention & Care – Building Models for the Future Project
TB REACH Ethiopia
TB REACH Nigeria
TB REACH Philippines
TB REACH Tanzania

KNCV Webinar: Impact of COVID-19: Hear the perspective of TB/MDR-TB patients and front line health care workers
KNCV Webinar: Contact Investigation for COVID-19: Lessons from TB Control Programs
KNCV Webinar ‘Infection prevention and control for COVID-19

Annual Report Summary 2019
KNCV 2-pager ASCENT
KNCV 2-pager Childhood TB
KNCV 2-pager Digital Health
KNCV 2-pager General
KNCV 2pager Right Diagnosis, Right Treatment
KNCV 2-pager TB Photovoices
KNCV 2-pager TB Stigma

Address

KNCV Tuberculosefonds
Maanweg 174
2516 AB Den Haag
+31 70 416 7222

OPEN IN GOOGLE MAPS

Postal address

Postbus 146
2501 CC Den Haag

More information

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.